Open access · CC-BY
via OpenAlex
Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure: Dose Response and Interaction with Angiotensin Receptor Blockade
Kalkidan G. Bishu, Ozgur Ogut, Sudhir S. Kushwaha, Selma F. Mohammed, Tomohito Ohtani, Xiaolei Xu, Frank V. Brozovich, Margaret M. Redfield
PLoS ONE · 2013 · ▲ 41 citations
Deregulated nutrient-sensing
Altered intercellular communication
Disabled macroautophagy
Rapamycin / mTOR inhibition
Human
Mouse
Abstract
While neurohumoral antagonists improve outcomes in heart failure (HF), cardiac remodeling and dysfunction progress and outcomes remain poor. Therapies superior or additive to standard HF therapy are needed. Pharmacologic mTOR(definition) inhibition by rapamycin(definition) attenuated adverse cardiac remodeling and dysfunction in experimental heart failure (HF). However, these studies used rapamycin doses that produced blood drug levels targeted for primary immunosuppression in human transplantation and therefore the immunosuppressive effects may limit clinical translation. Further, the relative or incremental effect of rapamycin combined with standard HF therapies targeting upstream regulators of cardiac remodeling (neurohumoral antagonists) has not been defined. Our objectives were to determine if anti-remodeling effects of rapamycin were preserved at lower doses and whether rapamycin effects were similar or additive to a standard HF therapy (angiotensin receptor blocker (losartan)). Experimental murine HF was produced by transverse aortic constriction (TAC). At three weeks post-TAC, male mice with established HF were treated with placebo, rapamycin at a dose producing immunosuppressive drug levels (target dose), low dose (50% target dose) rapamycin, losartan or rapamycin + losartan for six weeks. Cardiac structure and function (echocardiography, catheterization, pathology, hypertrophic and fibrotic gene expression profiles) were assessed. Downstream mTOR signaling pathways regulating protein synthesis (S6K1 and S6) and autophagy(definition) (LC3B-II) were characterized. TAC-HF mice displayed eccentric hypertrophy, systolic dysfunction and pulmonary congestion. These perturbations were attenuated to a similar degree by oral rapamycin doses achieving target (13.3±2.1 ng/dL) or low (6.7±2.5 ng/dL) blood levels. Rapamycin treatment decreased mTOR mediated regulators of protein synthesis and increased mTOR mediated regulators of autophagy. Losartan monotherapy did not attenuate remodeling, whereas Losartan added to rapamycin provided no incremental benefit over rapamycin alone. These data lend support to investigation of low dose rapamycin as a novel therapy in human HF.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1371/journal.pone.0081325
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Bishu, K.G., Ogut, O., Kushwaha, S.S., Mohammed, S.F., Ohtani, T., Xu, X., Brozovich, F.V., & Redfield, M.M. (2013). Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure: Dose Response and Interaction with Angiotensin Receptor Blockade. <em>PLoS ONE</em>. https://doi.org/10.1371/journal.pone.0081325
Vancouver
Bishu KG, Ogut O, Kushwaha SS, Mohammed SF, Ohtani T, Xu X, et al. Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure: Dose Response and Interaction with Angiotensin Receptor Blockade. PLoS ONE. 2013. doi:10.1371/journal.pone.0081325.
BibTeX
@article{kalkidan2013AntiRe,
title = {Anti-Remodeling Effects of Rapamycin in Experimental Heart Failure: Dose Response and Interaction with Angiotensin Receptor Blockade},
author = {Kalkidan G. Bishu and Ozgur Ogut and Sudhir S. Kushwaha and Selma F. Mohammed and Tomohito Ohtani and Xiaolei Xu and Frank V. Brozovich and Margaret M. Redfield},
journal = {PLoS ONE},
year = {2013},
doi = {10.1371/journal.pone.0081325},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Deep Blue (University of Michigan) 2023
Preprint · OA
Investigating the Effects of High Intensity Exercise in a Preclinical Mouse Model of Hypertrophic Cardiomyopathy
Molecular Medicine Reports 2021
Open access · CC-BY
Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin‑mediated autophagy
Journal of Clinical Investigation 2018
Open access · OA
Mitochondrial dysfunction in pathophysiology of heart failure
The Science Journal of the Lander College of Arts and Sciences 2021
Preprint · OA
Rapamycin and Metformin in Treating COVID-19
Annals of Clinical and Translational Neurology 2019
Open access · CC-BY
Exploring mTOR inhibition as treatment for mitochondrial disease
Experimental & Molecular Medicine 2020
Open access · CC-BY